Gabriel N. Hortobagyi, MD: Expert Perspective on the MONALEESA-2 Findings for HR-Positive, HER2-Negative Breast Cancer

Posted: Wednesday, October 13, 2021

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical implications of data showing the benefits of ribociclib combined with endocrine therapy for women with hormone receptor–positive, HER2-negative advanced breast cancer, the best way to administer this regimen, managing treatment-related adverse effects, and the evolving treatment landscape.